“…14 The spirocyclic β-lactam 157 (Figure 2), supported on superparamagnetic Fe 3 O 4 @SiO 2 nanoparticles, enhanced the antibacterial activity in comparison with the corresponding spirocyclic β-lactam, which was supposed to be due to the synergic effect of the Fe 3 O 4 @SiO 2 /β-lactam combination. 102,103 A number of novel spiro[azetidine-2,3 ' -indole]-2 ' ,4(1 ' H)-dione derivatives have been tested for anti-breast cancer activity, however, only 3-chloro-1-(o-tolyl)spiro[azetidine-2,3'-indoline]-2',4-dione 158 (Figure 2) displayed a significant cytotoxicity (IC 50 = 22.75-25.18 μM) for breast cancer cell lines after 48 h, which is comparable to the standard control drug doxorubicin. 104 Recently, ((2S,3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-diazaspiro [3.4]octan-2-yl)butanamide) 159 (Figure 2) has been examined for in vitro and in vivo pharmalogical properties.…”